Evidence map›Paper›PMID 38713628›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

THEMIS promotes T cell development and maintenance by rising the signaling threshold of the inhibitory receptor BTLA.

Suzanne Mélique, Aurélie Vadel, Nelly Rouquié, Cui Yang, Cyrielle Bories, Coline Cotineau, Abdelhadi Saoudi, Nicolas Fazilleau, Renaud Lesourne

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Focusing on CD8Journal of experimental & clinical cancer research : CR · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Suzanne MéliqueToulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse 31024, France.
Aurélie VadelToulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse 31024, France.
Nelly RouquiéToulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse 31024, France.ORCID 0000-0002-2347-9160
Cui YangToulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse 31024, France.ORCID 0000-0001-9410-1942
Cyrielle BoriesToulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse 31024, France.ORCID 0000-0002-3648-1710
Coline CotineauToulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse 31024, France.
Abdelhadi SaoudiToulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse 31024, France.ORCID 0000-0001-7015-8178
Nicolas FazilleauToulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse 31024, France.ORCID 0000-0002-3574-5614
Renaud LesourneToulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse 31024, France.ORCID 0000-0003-3816-7087

Funding

Agence Nationale de la Recherche (ANR) ANR-20-CE15-0002Agence Nationale de la Recherche (ANR) ANR-20-CE15-0005China Scholarship Council (CSC) No funding numberFondation ARC pour la Recherche sur le Cancer (ARC) No funding numberFondation pour l'Aide à la Recherche sur la Sclérose en Plaques (ARSEP) No funding number
6 · The paper itself

Abstract

The current paradigm about the function of T cell immune checkpoints is that these receptors switch on inhibitory signals upon cognate ligand interaction. We here revisit this simple switch model and provide evidence that the T cell lineage protein THEMIS enhances the signaling threshold at which the immune checkpoint BTLA (B- and T-lymphocyte attenuator) represses T cell responses. THEMIS is recruited to the cytoplasmic domain of BTLA and blocks its signaling capacity by promoting/stabilizing the oxidation of the catalytic cysteine of the tyrosine phosphatase SHP-1. In contrast, THEMIS has no detectable effect on signaling pathways regulated by PD-1 (Programmed cell death protein 1), which depend mainly on the tyrosine phosphatase SHP-2. BTLA inhibitory signaling is tuned according to the THEMIS expression level, making CD8+ T cells more resistant to BTLA-mediated inhibition than CD4+ T cells. In the absence of THEMIS, the signaling capacity of BTLA is exacerbated, which results in the attenuation of signals driven by the T cell antigen receptor and by receptors for IL-2 and IL-15, consequently hampering thymocyte positive selection and peripheral CD8+ T cell maintenance. By characterizing the pivotal role of THEMIS in restricting the transmission of BTLA signals, our study suggests that immune checkpoint operability is conditioned by intracellular signal attenuators.

Indexed as

CD8-Positive T-LymphocytesIntercellular Signaling Peptides and ProteinsReceptors, ImmunologicSignal TransductionAnimalsCD4-Positive T-LymphocytesCell DifferentiationHumansMiceProgrammed Cell Death 1 ReceptorProtein Tyrosine Phosphatase, Non-Receptor Type 6T-LymphocytesBTLA protein, mouseIntercellular Signaling Peptides and ProteinsProgrammed Cell Death 1 ReceptorProtein Tyrosine Phosphatase, Non-Receptor Type 6Receptors, ImmunologicT cell Ig and ITIM domain protein, mousethemis protein, mouseBTLAimmune checkpointsignalingT cellTHEMIS

Identifiers

PMID38713628
PMCPMC11098085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.